Sonostics is a Binghamton University medical device spin-off company with a focus on muscle assessment and re-education. Our R&D efforts have a particular emphasis on calf muscle pump activity and its role in maintaining effective performance of the cardiovascular system.

Sonostics was initially formed as a New York Corporation in 2008 to commercialize vibromyography (VMG) technology developed at Binghamton University. VMG technology permits measurement of absolute muscle force and so allows identification of the muscle imbalances which commonly lead to neck, back, and joint pain. VMG technology was subsequently licensed to BioPac, Inc. which continues to incorporate the technology into their physiologic measurement equipment.

In 2014, Sonostics reincorporated as a Delaware C-Corp and shifted its focus from the diagnostic technologies to interventions directed towards correcting muscle imbalances. Our specific focus is on the development of non-invasive methods to activate the soleus muscles, or what are commonly called our second hearts. Inadequate second heart activity leads to health complications associated with lower limb fluid pooling, complications associated with low cardiac output, and health complications associated with chronically low blood flow to the brain.

Sonostics has developed two second heart stimulation devices based on micromechanical stimulation technology, the MM-100, introduced in 2016, and the HeartPartner, introduced in 2018. These devices have been utilized in more than a dozen clinical/physiologic studies to identify the relationship between soleus muscle activity, cardiovascular system performance, and health outcomes associated with enhanced second heart activity. Our HeartPartner product is currently available for purchase at The HeartPartner Store. In 2024 Sonostics plans to introduce its next generation, magnetic neuro-modulation based second heart stimulation product.